Neuromuscular Disorders

Advancing myasthenia gravis treatment: RAISE trial of zilucoplan 2:27
Advancing myasthenia gravis treatment: RAISE trial of zilucoplan
James F. Howard Jr. • 26 Apr 2023
Putting the MND community at the heart of MND Scotland’s research strategy 3:23
Putting the MND community at the heart of MND Scotland’s research strategy
Jane Haley • 24 Apr 2023
Study design for the PREVAIL trial: Phase III study of ALXN1720 in adults with myasthenia gravis 1:52
Study design for the PREVAIL trial: Phase III study of ALXN1720 in adults with myasthenia gravis
James F. Howard Jr. • 26 Apr 2023
MND-SMART: the adaptive platform trial investigating potential treatments for MND 3:22
MND-SMART: the adaptive platform trial investigating potential treatments for MND
Jane Haley • 24 Apr 2023
The MND Scotland strategy: making time count 2:18
The MND Scotland strategy: making time count
Jane Haley • 24 Apr 2023
Developing antibodies against pathogenic TDP-43 in ALS 3:42
Developing antibodies against pathogenic TDP-43 in ALS
Johanne Kaplan • 30 Mar 2023
Key findings from Phase IIa study of PrimeC in ALS patients 3:07
Key findings from Phase IIa study of PrimeC in ALS patients
Shiran Salomon-Zimri • 27 Mar 2023
Novel combination therapy PrimeC in ALS: biomarker data & launch of Phase II trial 10:55
Novel combination therapy PrimeC in ALS: biomarker data & launch of Phase II trial
Shiran Salomon-Zimri • 27 Mar 2023
Informing iRBD patients about potential PD development 1:32
Informing iRBD patients about potential PD development
Michael Ugrumov • 30 Mar 2023
CONy 2023: controversies in neuroimmunology, PD and AD 7:53
CONy 2023: controversies in neuroimmunology, PD and AD
Amos Korczyn • 9 Mar 2023
The significance of glial cells in the pathophysiology of ALS 3:23
The significance of glial cells in the pathophysiology of ALS
Serge Przedborski • 16 Sep 2022
Losmapimod as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD) 8:29
Losmapimod as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD)
Christopher Morabito • 11 Apr 2022
Updates on peripheral autoimmune neurological conditions 2:44
Updates on peripheral autoimmune neurological conditions
Divyanshu Dubey • 12 Apr 2022
Diagnostic work up of autoimmune neurological conditions 3:13
Diagnostic work up of autoimmune neurological conditions
Divyanshu Dubey • 12 Apr 2022
Immunotherapy strategies for autoimmune disorders of the nervous system 1:43
Immunotherapy strategies for autoimmune disorders of the nervous system
Divyanshu Dubey • 12 Apr 2022
Phase II extension trial of CNM-Au8 in ALS 1:51
Phase II extension trial of CNM-Au8 in ALS
Matthew Kiernan • 4 Apr 2022
The content of VJNeurology is intended for healthcare professionals